Use of the cathelicidin LL-37 and derivatives thereof for wound healing

US7452864B2 · kind B2 · utility

Assignee

• Lipopeptide AB · SE

Inventors

• Mona Ståhle-Bäckdahl · Stockholm, SE
• Johan Heilborn · Stockholm, SE
• Anders Carlsson · Lund, SE
• Conny Bogentoft · Nordstraße, SE

Key dates

• Filing date: Jan 28, 2004
• Grant date: Nov 18, 2008
• Expiry date: Dec 8, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2500/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.